Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b FOLFIRI plus ramucirumab in Japanese patients with metastatic colorectal cancer after bevacizumab + oxaliplatin + fluoropyrimidine
jRCT2080221386Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ramucirumab in colorectal cancer (CRC), sponsored by Eli Lilly and Company.
02
Drugs
ramucirumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080221386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221386.